Form 8-K ImmunityBio, Inc. For: Aug 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
ImmunityBio's (IBRX) NantCell Statement on Sorrento's (SCLX) Failure to Pay Settlement
September 1, 2023 8:40 AM EDTAs previously disclosed, on August 14, 2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement involving Sorrento Therapeutics, Inc.s (Sorrento) litigation claims against ImmunityBio (NASDAQ: IBRX) wholly-owned subsidiary NantCell, Inc. (NantCell) and others, such that the settlement is binding on the parties. The settlement is described in detail in the motion filed with the bankruptcy court on June 6, 2023 in In re... More
